Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06613217 | Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | Pacylex PharmaceuticalsINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06773312 | BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2025 |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05983237 | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 50 | Jun GuoOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06069570 | Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases | recruiting | Phase 1 | 48 | Kiromic BioPharma Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05472558 | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 95 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06494943 | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC | recruiting | Phase 1 / Phase 2 | 27 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06835140 | CD123-CD16-NK Cells Immunotherapy for AML(CD123-CD16-NK) | recruiting | Phase 1 | 9 | Chunji GaoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06651866 | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06737523 | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | recruiting | Phase 1 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06088888 | TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05066412 | Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC | recruiting | Phase 1 | 12 | University Hospital, GenevaOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06822868 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Kai HuOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06613009 | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 1 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Feb 11, 2025 | clinicaltrials |
| NCT06642792 | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06464861 | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma(CD19-CARNK/T) | recruiting | Phase 1 | 52 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05937438 | Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma | recruiting | Phase 1 / Phase 2 | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05504278 | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | recruiting | Phase 1 | 144 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06071013 | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | recruiting | Phase 1 / Phase 2 | 20 | China Medical University HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04807881 | Phase Ib Clinical Study of Keynatinib | recruiting | Phase 1 | 75 | Medolution Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone(KPT-IST-391) | recruiting | Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06778603 | B7-H3 NIR Imaging for Osteosarcoma Surgery(ROLN-B7-H3) | recruiting | Phase 1 / Phase 2 | 32 | Peking University People's HospitalOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06186414 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | recruiting | Phase 1 | 152 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06581419 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 78 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06703255 | A Phase 2 Study of HX301 in Patients with High-grade Giloma | recruiting | Phase 1 / Phase 2 | 72 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06572813 | Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer(CISPD-7) | recruiting | Phase 1 / Phase 2 | 63 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma(UHKT-CAR19-01) | recruiting | Phase 1 | 10 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2025source: clinicaltrials